We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

2 hedge funds and large institutions have $18K invested in Trillium Therapeutics Inc. in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 177 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 181 → 2 (-179)

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 177

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $1.38B → $18K (-$1.38B)

Holders
2
Holders Change
-179
Holders Change %
-98.9%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
177
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$107M
2
NMC
NEA Management Company
Maryland
-$101M
3
ACA
Avoro Capital Advisors
New York
-$100M
4
EAM
Eventide Asset Management
Massachusetts
-$91.8M
5
MF
Magnetar Financial
Illinois
-$57.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
LOAMU
101
Lombard Odier Asset Management (USA)
New York
– -$878K -50,000 Closed
SCS
102
Syquant Capital SAS
France
– -$878K -50,000 Closed
Manulife (Manufacturers Life Insurance)
103
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1.1M -49,618 Closed
Wellington Management Group
104
Wellington Management Group
Massachusetts
– -$865K -49,258 Closed
Two Sigma Advisers
105
Two Sigma Advisers
New York
– -$825K -47,000 Closed
KPF
106
K2 Principal Fund
Ontario, Canada
– -$790K -45,000 Closed
RJA
107
Raymond James & Associates
Florida
– -$738K -42,037 Closed
CSS
108
Cubist Systematic Strategies
Connecticut
– -$734K -41,816 Closed
VOYA Investment Management
109
VOYA Investment Management
Georgia
– -$681K -38,780 Closed
MIM
110
MetLife Investment Management
New Jersey
– -$677K -38,562 Closed
Invesco
111
Invesco
Georgia
– -$660K -37,627 Closed
Bank of Montreal
112
Bank of Montreal
Ontario, Canada
– -$666K -37,230 Closed
CC
113
Centiva Capital
New York
– -$690K -36,815 Closed
Citigroup
114
Citigroup
New York
– -$634K -36,104 Closed
BCM
115
BCK Capital Management
Connecticut
– -$604K -34,394 Closed
D.E. Shaw & Co
116
D.E. Shaw & Co
New York
– -$597K -34,014 Closed
CCM
117
Chicago Capital Management
Illinois
– -$562K -32,000 Closed
Verition Fund Management
118
Verition Fund Management
Connecticut
– -$536K -30,530 Closed
AFM
119
Anson Funds Management
Texas
– -$527K -30,000 Closed
MLICM
120
Metropolitan Life Insurance Company (MetLife)
New York
– -$518K -29,523 Closed
VFA
121
Values First Advisors
Tennessee
– -$452K -25,768 Closed
William Blair & Company
122
William Blair & Company
Illinois
– -$442K -25,150 Closed
PCM
123
Prelude Capital Management
New York
– -$430K -24,485 Closed
Russell Investments Group
124
Russell Investments Group
United Kingdom
– -$420K -23,927 Closed
Ameriprise
125
Ameriprise
Minnesota
– -$405K -23,062 Closed
3 4
5
6 7

TRIL Hedge Fund Activity: Q4 2021 in Review

2 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2021, worth a combined $18K — down 100% from $1.38B a quarter earlier.

Sellers outnumbered buyers: 177 funds closed out of TRIL and 1 opened new positions — a net loss of 176 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $107M sold.

  • 2 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2021, down from 181 in Q3 2021.
  • Funds reported $18K of Trillium Therapeutics Inc. stock for Q4 2021, down 100% quarter-over-quarter.
  • 1 fund opened new Trillium Therapeutics Inc. positions in Q4 2021 and 177 closed out, a net change of -176 holders.
  • The largest Trillium Therapeutics Inc. seller in Q4 2021 was BlackRock, an estimated $107M sold.

Based on aggregated 13F filings for Q4 2021.